We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
RNA Interference (RNAi)-Based Anti-monkeypox Drug Discovery Solutions
With the worldwide outbreak of monkeypox virus infections causing skin and systemic diseases and in some cases death, it is imperative to find a reasonable solution against this virus. Creative Biolabs has been engaged in the life science industry for more than a decade, who is committed to providing a one-stop RNA interference (RNAi)-based anti-monkeypox drug discovery solution in the development of reliable virus products and monkeypox-related drugs.
Mechanism of RNAi
RNAi presents in mammalian cells and plants. RNAi is a natural gene regulatory process involved in post-transcriptional mechanism that silences genes via chromatin remodeling, inhibition of protein translation, or direct cleavage of target RNA. RNAi can be stimulated by interfering RNAs, including microRNA (miRNA), the short interfering RNA (siRNA), and short hairpin RNA (shRNA). The final effector of expressed RNAi activator pathways is the ribonucleoproteins complex (RISC), which is catalyzed by the Argonaute (Ago) family of proteins. The PAZ domain and the PIWI domain of the Ago proteins can bind to miRNA or siRNA and target RNA cleavage, respectively.
There are three mechanisms of gene silencing involved in RNAi. First, when the guide filament in RISC and target RNA match each other, the RISC functions its endonucleolytic activity to induce mRNA degradation. The endogenous siRNAs are involved in this condition. In addition, the pairing of the guide filament and endogenous miRNAs often faulty occurs with the 3' UTR of the target mRNA. In this case, the inhibition of translation of the target mRNA leads to gene silencing. Finally, RISC-associated Ago proteins can sequester the target mRNAs within specific cytoplasmic compartments (P bodies), in which target RNA degradation occurs.
Fig.1 An overview of biogenesis and intracellular processing of RNAi inducers. (Reza, 2021)
RNA interference (RNAi)-based Anti-Monkeypox Drug Discovery Solutions at Creative Biolabs
Investigating the interaction between the host and viruses plays a critical role in RNAi mechanistic studies and RNAi application in viral diseases. The gene regulatory property of RNAi can be used for medical purposes, as RNAi acts as a therapeutic tool that targets multiple phases of infectious virus lifecycle, including replication, transcription, assembly, and budding from target cells, which is effective for both RNA and DNA viruses. Creative Biolabs provides a full range of RNAi anti-monkeypox drug discovery solutions, promoting research from mechanism to clinical translational application.
MicroRNAs-based Anti-Monkeypox Drug Discovery Solutions
miRNAs with stem-loop structures are synthesized by the cells from specific RNA transcripts. They are non-coding RNA molecules that play a role in regulating the post-transcriptional process of genes by binding to the 3'-UTR of target genes. Our miRNAs-based anti-monkeypox drug discovery solutions enable researchers to discover potential miRNA therapeutics against monkeypox.
Short interfering RNAs-based Anti-Monkeypox Drug Discovery Solutions
siRNAs are molecules that are completely complementary to the mRNA sequences of the viral proteins, therefore blocking the transcription of the viral proteins. The advantage of synthesized siRNAs is that these molecules do not need to reach the nucleus to provoke therapeutic effects. We offer chemical modification services for synthesized siRNA, which make the siRNAs more stable and less toxic. Thus, the modified siRNAs can improve the efficiency of gene silencing and optimize the efficacy of anti-virus. The chemical modifications by us include modification of the 2' position of the ribose ring and modification of the boranophosphate linkage. siRNAs could be effectively applied in the prevention of viral infection against poliovirus, hepatitis C virus, etc., inhibition of the viral antigen expression, viral gene transcription and replication, and viral particle assembly. Our siRNA-based anti-monkeypox drug discovery solutions allow our global clients to develop stable and reliable siRNA therapeutic against monkeypox.
Short hairpin RNA-based Anti-Monkeypox Drug Discovery Solutions
shRNAs are transcribed within the nucleus to downregulate the expression of the viral gene. Compared to other forms of RNAi, shRNA-induced RNAi to silence genes is more persistent. Our shRNA solutions are applied in the suppression of monkeypox antigen expression, prevention of monkeypox infection, and inhibition of monkeypox gene transcription and replication.
As an industry-leading service provider, Creative Biolabs is committed to offering a full range of monkeypox products and specialized solutions equipped with state-of-the-art high-throughput screening, artificial intelligence, in vitro and in vivo platforms. Our experienced team helps you design customized RNAi-based anti-monkeypox agent discovery programs. Please do not hesitate to contact us to learn more details.
Reza, M. S.; et al. The Possibility of Nucleic Acids to Act as Anti-Viral Therapeutic Agents—A Review. Open Journal of Medical Microbiology. 2021, 11(3): 198-248.